October 14, 2020 -- Thermo Fisher Scientific will operate a $130 million facility in Singapore that will be used to develop two new sterile filling lines, extending capacity to develop and manufacture therapies and vaccines.
The facility, which was supported by the Singapore Economic Development Board, will include a high-speed sterile line approved for live virus filling and an additional line for standard filling and finishing. When it opens in 2022, it also will have cleanroom capacity, labs, warehousing, and offices to support production. The facility is expected to manufacture up to 30 million sterile doses per month, according to the company.
The facility is being built to meet pharmaceutical product demand in the Asia-Pacific region and to respond more effectively to future health emergencies, like COVID-19.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
